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Background: Erythropoiesis-stimulating agents
(ESAs) increase red blood cell production in patients
with chemotherapy-induced anemia (CIA). In Europe,
short-acting ESAs (epoetin alfa, epoetin beta, epoetin
zeta, and epoetin theta) and a long-acting ESA
(darbepoetin alfa) are available to treat CIA.
Objective: This systematic review aimed to deter-
mine potential dose efﬁciency associated with the use
of different ESAs for the treatment of CIA according
to European labeling.
Methods: A systematic review of ESA studies with
starting doses according to European labeling was
conducted according to published methodology.
Measures of dose efﬁciency were deﬁned as mean
weekly doses to achieve target hemoglobin level or
ﬁnal dose and dose adjustments (dose increase, de-
crease, or withheld). Electronic databases and grey
literature sources were searched up to July 2012. Data
were selected for analysis using an evidence hierarchy
and quantitatively analyzed to assess statistical homo-
geneity. Where pooling of data was not appropriate, a
narrative summary with descriptive statistics (medians
and ranges) was reported.
Results: Fifty-ﬁve studies met the inclusion criteria.
Twenty-ﬁve studies considered to represent the highest
level of evidence were extracted and included in the
analysis. The analysis showed a high degree of
statistical heterogeneity, often precluding meta-
analysis. The patients included in the analysis were
representative of those encountered in clinical prac-
tice, and patient characteristics were similar between
the short-acting and the darbepoetin alfa groups.
Mean weekly doses appeared 30% lower with594darbepoetin alfa versus short-acting ESAs (median,
136.5 μg or 27,300 IU [range, 21,560–38,260 IU] vs
38,230 IU [range, 31,634–42,714 IU], respectively),
resulting in a mean weekly dose ratio of 1:280.
Darbepoetin alfa patients appeared to need fewer
dose increases compared with short-acting ESAs
(pooled, 0.75%; I2 ¼ 21% vs median 26.6% [range,
7.6%–44.6%]) and more dose decreases (median,
74% [range, 57%–75%] vs 22% [range, 2.8%–
59%]). A similar percentage of darbepoetin alfa and
short-acting ESA patients required a dose to be with-
held (20% and 33% [2 studies] vs median 33.2%
[range, 12.6%–51.1%]).
Conclusions: Statistical heterogeneity between stud-
ies was high, although clinically the studies represented
medical practice. Without randomized clinical trials
directly comparing darbepoetin alfa and short-acting
ESAs, these ﬁndings are tentative and future research is
warranted. This review shows that good-quality, reli-
able data from head-to-head trials are lacking. The best
available evidence comes from prospective ESA-arm
data. Mean weekly doses, dose increases, and dose
decreases suggest a dose efﬁciency for darbepoetin alfa
compared with short-acting ESAs. (Clin Ther.
2014;36:594–610) & 2014 The Authors. Published by
Elsevier HS Journals, Inc. All rights reserved.
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Anemia is a relatively common condition in people
with cancer and can occur due to cancer treatment
(chemotherapy-induced anemia; CIA) or the disease
itself (anemia of cancer). It has been reported that up
to 60% of patients with solid tumors and lymphoma
may experience anemia, and that in those patients
receiving myelosuppressive chemotherapy and/or ra-
diation, this incidence can rise to 70% to 90%.1
Platinum-based therapies in particular are well-known
to induce anemia due to combined toxic effects on the
bone marrow and kidneys.2
Options available for the management of CIA
include adjustments to the cancer therapy regimen,
iron supplementation, and red blood cell transfusions
(RBCTs). Erythropoiesis-stimulating agents (ESAs)
provide an alternative to RBCTs by increasing RBC
production. It has been shown in multiple controlled
trials that ESAs can increase hemoglobin (Hb) levels
and reduce RBCT requirements.3 ESAs fall into 2
main categories: (1) short-acting ESAs (epoetin alfa,*
epoetin zeta,† epoetin beta,‡, and epoetin theta§); and
(2) long-acting ESAs (darbepoetin alfaJ) (Table I4–14).
Short-acting ESAs are generally administered three
times per week or once weekly.4–13 Because darbe-
poetin alfa has a longer half-life, it can be adminis-
tered less frequently than short-acting ESAs (every 3
weeks compared with once-weekly dosing),14 which
may lead to payer savings as well as a reduced burden
on patients. Research in CIA has suggested that
darbepoetin alfa may offer savings with respect to*Trademarks: Eprexs (manufactured by Ortho Biologics LLC,
and distributed and marketed by Ortho Biotech Products, LP,
Bridgewater, New Jersey, a subsidiary of Johnson & Johnson),4
Epogens (Amgen Inc, Thousand Oaks, California),4 and
Procrits (Amgen Inc)5; biosimilars: Abseameds (manu-
factured by Sandoz GmbH, Austria),6 Binocrits,
(manufactured by Sandoz GmbH, Austria)7 and Epoetin
alfa Hexals (Lek dd, Ljubljana, Slovenia, and Rentschler
Biotechnologie, Laupheim, Germany; marketed by Hexal AG,
Holzkirchen, Germany).8
†Trademarks: RetacritTM (Hospira, Inc, Lake Forest, Illinois)9
and Silapos (Stada Arzneimittel AG, Bad Vilbel, Germany).10
‡Trademark: NeoRecormons (F. Hoffmann-La Roche Ltd,
Basel, Switzerland).11
§Trademarks: Eporatios (Sicor Biotech, Vilnius, Lithuania;
marketed by Ratiopharm UK Ltd, Portsmouth, United King-
dom),12 Biopoins (Merckle Biotec, Ulm, Germany, marketed
by Teva Deutschland GmbH, Ulm, Germany).13
JTrademark: Aranesps (Amgen Inc).14
April 2014the number of doses required and so has greater dose
efﬁciency to achieve the desired clinical outcome.15 It
has also been shown to be the case in nephrology that,
when using an initial conversion ratio of 200:1
between darbepoetin alfa and other ESAs, target Hb
values can be maintained and a dose saving can be
achieved,16 but a similar level of evidence has not been
reported in cancer patients. The initial conversion
ratio (200:1) follows the indication in European
labeling for the treatment of CIA to achieve
satisfactory Hb targets.14
The aim of this systematic review was to use the
best evidence available to further investigate relative
dose efﬁciency in CIA patients using the European-
recommended initial conversion ratio of 200:1. For
the purposes of this review, dose efﬁciency was
deﬁned as the mean weekly doses of darbepoetin alfa
and short-acting ESAs (including biosimilars) required
to achieve target Hb levels in patients with CIA.
Additionally, dose adjustments, including increases,
decreases, and doses withheld were investigated.
MATERIALS AND METHODS
To reduce the risks for bias and error, this review
adhered to a prespeciﬁed protocol and methods
recommended by the Cochrane Collaboration,17 and
the Centre for Reviews and Dissemination (York,
United Kingdom),18 which are accepted by Health
Technology Assessment agencies.
Inclusion/Exclusion Criteria
This review included head-to-head studies compar-
ing darbepoetin alfa with the short-acting ESAs
(epoetin alfa, epoetin beta, epoetin theta, and epoetin
zeta). We also included ESA-arm data (from retro-
spective or prospective, single-arm studies or compa-
rative cohort studies/randomized controlled trials
[RCTs]) in which only one study arm received a
relevant ESA treatment. Dose-ﬁnding studies were
excluded. Eligible ESA treatments had to be in
accordance with current European licensing regula-
tions with respect to the starting dose (Table I). Adults
aged Z18 years with any type of nonmyeloid cancer
who were receiving chemotherapy or chemotherapy
plus radiotherapy in addition to an ESA for the
treatment of CIA (but not for anemia of cancer or
myelodysplastic syndrome), were included.
Eligible studies were published articles and confer-
ence abstracts that reported on the dose efﬁciency of595
Clinical TherapeuticsESAs. Dose efﬁciency was deﬁned as the mean weekly
dose to achieve the target Hb level. Dose-adjustment
data (the number of patients who required an ESA
dose increase, decrease, and/or the ESA dose withheld)
were also of interest. At least 1 of the outcomes of
interest had to have been reported for a study to have
been included. Studies in which dose changes were not
allowed and those in which the reporting of the
methods or outcomes were unclear, were excluded.
Literature Searches
In addition to the Cochrane Central Register of
Controlled Trials (Cochrane Library Issue 6:2012)
(Wiley), the following databases were searched from
inception to July 2012: MEDLINE (1946-2012/06/
wk4) (OvidSP), MEDLINE In-Process Citations and
Daily Update (up to 2012/07/09) (OvidSP), and
EMBASE (1974-2012/wk27) (OvidSP). No language
limitations were applied. The main key words in-
cluded epoetin alfa, epoetin beta, darbepoetin alfa,
erythropoietin, erythropoiesis-stimulating agents, and
ESAs and their brand names, in combination with
cancer or neoplasms or chemotherapy. The main
EMBASE strategy was independently peer reviewed
by a second information specialist, using the PRESS-
EBC checklist.19 In addition, a manual check of the
reference lists of all included papers and relevant
reviews was performed. Abstract books were also
searched (2010–2012) for the following conferences
up to August 31, 2012: American Society of Clinical
Oncology (ASCO); European Society for Medical
Oncology (ESMO); American Society of Hematology
(ASH); and the European Haematology Association
(EHA).
All identiﬁed references were downloaded in End-
Note X4 software (Thomson Reuters, Philadelphia,
Pennsylvania) and de-duplicated before further assess-
ment and handling. The ﬁnal list of included papers
was also used to check on PubMed for retractions and
errata.20–22 Full details of the search strategies utilized
are available on request.
Study Selection and Data Extraction
The study selection process was performed by 2
reviewers working independently. For each included
study, data were extracted into a speciﬁcally devel-
oped spreadsheet in Excel 2007 (Microsoft Corpora-
tion, Redmond, Washington). One reviewer extracted
the study data and a second reviewer independently596reviewed the data against the original paper for com-
pleteness and accuracy. The methodological quality (risk
for bias) of each study was assessed using the criteria of
Downs and Black,23 which included the reporting of the
aims, outcomes, interventions, and patient character-
istics; loss to follow-up; statistical analysis methods; the
reporting of results; and assessment of internal and
external validity. The quality assessments were per-
formed independently by 2 reviewers. Any discrep-
ancies between reviewers during data extraction or
quality assessments were resolved through consensus
or consultation with a third reviewer.
Data Analysis
Given that only 1 head-to-head study comparing
darbepoetin alfa and a short-acting ESA was identi-
ﬁed, an a priori evidence hierarchy was used to select
the next best available evidence. In accordance with
this hierarchy, ESA-arm data in which Z100 patients
received a relevant ESA regimen with a dose licensed
according to European Medicines Agency (EMA)
labeling4–8,10,11,13–24 (Table I) were used from any
relevant prospective comparative study (ie, ESA vs
control or ESA vs ESA) or single-arm study.
For each outcome from each data set (head-to-head
data and ESA-arm data), a narrative summary of all of
the included studies was presented. Any factors that
would introduce a risk for bias or limit the general-
izability of the ﬁndings were described. In addition,
where possible, a quantitative analysis was performed.
The mean weekly ESA dose was extracted or
calculated for each study arm, together with the
associated 95% CIs and presented on forest plots. If
a study reported a mean but no SD, the SD was
imputed in accordance with accepted Cochrane Col-
laboration methods17 by replacing missing SDs with
the mean of the reported SDs for the same drug.
For studies reporting a weight-based dose, the
reported dose was multiplied by the mean patient
weight (if reported) or a mean weight of 70 kg. This
weight was based on the average of 7 of the included
studies that reported mean patient weight.25–31 In
these studies, the weight was 70 kg (range of means,
64.7 kg25 to 74.9 kg28); this included 1 study in which
a weight-based dosing schedule was used.25
Dose-adjustment parameters such as ESA dose
increase, decrease, or ESA dose withheld can provide
additional information about the dose efﬁciency of
ESAs. Therefore, the numbers of patients requiring aVolume 36 Number 4
Table I. Current European licensing regulations for erythropoiesis-stimulating agent (ESA) regimens.
Dosing Regimen
ESA
Fixed Dose,
IU QW Weight-Based Dose Initial Dose Hb Increase o1 g/dL
Hb Increase
Z1 g/dL
Hb Increase
42 g/dL
Hb Level at Which
Therapy Should Be
Discontinued, g/dL
Epoetin alfa* 30,000 or 40,000 150 IU/kg TIW or
450 IU/kg QW
150 IU/kg SC TIW (or 450
IU/kg QW SC) for 4 wk
(target Hb, r12 g/dL)
300 IU/kg TIW for 4 wk (RC
increase also should be o40,000
mL); then if Hb increase still o1
g/dL and RC increase o40,000 mL,
discontinue treatment
Continue current
dose (same if
RC increase
Z40,000 mL)
25%–50% dose
reduction
(same if Hb 412
g/dL)
413
Epoetin zeta† 40,000 150 IU/kg TIW or
450 IU/kg QW
150 IU/kg SC TIW (or 450
IU/kg QW SC) for 4 wk
(target Hb, 10–12 g/dL)
300 IU/kg TIW for 4 wk (RC
increase also should be o40,000
mL); then if Hb increase still o1
g/dL and RC increase o40,000 mL,
discontinue treatment
Continue current
dose (same if
RC increase
Z40,000 mL)
25%–50% dose
reduction
412
Epoetin beta‡ 30,000 450 IU/kg QW 30,000 IU QW SC for 4 wk
(independent of weight)
(target Hb, 10–12 g/dL)
60,000 IU QW for 4 wk; then if Hb
increase still o1 g/dL, discontinue
treatment
Continue current
dose
25%–50% dose
reduction
(same if Hb 412
g/dL)
413
Epoetin theta§ 20,000 — 20,000 IU QW SC for 4 wk
(independent of weight)
(target Hb, 10–12 g/dL)
40,000 IU QW for 4 wk; then
60,000 IU QW should be
considered. If after 12 wk Hb
increase still o1 g/dL,
discontinue treatment.
Continue current
dose
25%–50% dose
reduction
413
Darbepoetin
alfa‖
33,333¶ or 500
mg Q3W or
6.75 mg/kg Q3W 500 μg (6.75 μg/kg) Q3W
(or 2.25 μg/kg QW) for 9 wk
(target Hb, 10–12 g/dL)
Discontinue treatment Continue current
dose
25%–50% dose
reduction
413 (or 4 wk after
completion of
chemotherapy)
30,000¶ or 150
mg QW
2.25 μg/kg QW
Hb ¼ hemoglobin; RC ¼ reticulocyte count; SC ¼ subcutaneously.
*Trademarks: Eprexs (manufactured by Ortho Biologics LLC, and distributed and marketed by Ortho Biotech Products, LP, Bridgewater, New Jersey, a subsidiary of
Johnson & Johnson),4 Epogens (Amgen Inc, Thousand Oaks, California),4 and Procrits (Amgen Inc)5; biosimilars: Abseameds,6 Binocrits,7 and Epoetin alfa
Hexals (Lek d. d. Ljubljana, Slovenia, and Rentschler Biotechnologie, Laupheim, Germany; marketed by Hexal AG, Holzkirchen, Germany).8
†Trademarks: RetacritTM (Hospira, Inc, Lake Forest, Illinois)9 and Silapos (Stada Arzneimittel AG, Bad Vilbel, Germany).10
‡Trademark: NeoRecormons (F. Hoffmann-La Roche Ltd, Basel, Switzerland).11
§Trademarks: Eporatios (Sicor Biotech, Vilnius, Lithuania; marketed by Ratiopharm UK Ltd, Portsmouth, United Kingdom),12 Biopoins (Merckle Biotec, Ulm,
Germany, marketed by Teva Deutschland GmbH, Ulm, Germany).13
‖Trademark: Aranesps (Amgen Inc).14
¶Based on a 1:200 dose conversion ratio to IU.14
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Clinical Therapeuticsdose adjustment were extracted for the relevant ESA
group from each study and are reported as percen-
tages. The percentages (95% CI) of patients with each
different outcome were also reported on forest plots.
For all outcomes, statistical heterogeneity or the
amount of variation between the results of the studies
was assessed by visual assessment of the degree of
overlap between the 95% CIs from the different
studies and by using the I2 statistic, which describes
the percentage of the variability in the results caused
by differences between studies rather than by
chance.17 Values of Z50% were considered to rep-
resent substantial heterogeneity, and values between
75% and 100%, high heterogeneity. In cases in which
heterogeneity was high (475%), statistical pooling
was considered inappropriate and results were
summarized using descriptive statistics (medians
and ranges). Possible reasons for the high level of
heterogeneity were explored by grouping the studies
according to ESA drug, iron supplementation, baseline
Hb level, target Hb level, chemotherapy regimen,
tumor type, and stopping rule32 (in studies in which
ESA treatment was withdrawn if Hb levels exceeded
13 g/dL and reinstated when Hb levels were r12 g/
dL). If heterogeneity was low or moderate (o50%),
then results were pooled using an inverse-variance
random-effects model. Review Manager (RevMan)
(CVersion 5.2. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2012) was used
for plots and analyses.
RESULTS
Study Selection
Literature searches of MEDLINE, MEDLINE In-
Process & Daily Update, EMBASE and CENTRAL
retrieved 8680 titles/abstracts through July 2012.
After de-duplication, a total of 6687 titles/abstracts
were screened, and 6324 papers were excluded as
having no relevance to the review. Full papers of 363
potentially relevant references were selected for fur-
ther examination. Of these, 302 papers were excluded
after further examination for the following reasons:
did not assess a relevant outcome/report any usable
outcome data (158 papers), not a licensed dose of the
relevant ESA (67), not a relevant study/design (38),
ESA type and dose not reported (20), not a relevant
population (11), or dose increases speciﬁed as not
permitted (1). Seven papers were unobtainable despite
efforts to retrieve them through electronic means and598through contacting the British Library. A total of 55
studies met the criteria for inclusion in the review.
Given the reliance on ESA-arm data, the a priori
evidence hierarchy was used to ensure that only the
best available ESA-arm data were included. This
resulted in the extraction and analysis of 25 studies
in total. The selected studies were all prospective in
design and had Z100 patients per arm (24 ESA arms
from 11 prospective single-arm studies, 9 RCTs
comparing different ESAs, 4 placebo-controlled trials,
and 1 RCT comparing darbepoetin alfa and short-
acting ESAs with both licensed dosages). A summary
of the identiﬁcation and selection of studies for
inclusion in this review is presented in Figure 1, in
accordance with the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses)
statement (http://www.prisma-statement.org/).
Study Characteristics
A summary of the characteristics of the 25 studies
included in this review is presented in Table II; for
further information on the individual studies, see
Supplemental Tables I to IV (in the online version
at http://dx.doi.org/10.1016/j.clinthera.2014.02.007).
The only head-to-head study comparing darbepoetin
alfa and short-acting ESAs was an RCT reported as a
conference abstract.33 This study compared the
treatment of 239 patients with solid or hematologic
tumors who received platinum-based and/or non–
platinum-based chemotherapy and either darbepoetin
alfa or epoetin alfa. In the remaining 24 studies
included in the ESA-arm analysis, a total of 12,028
patients (range, 10934 to 296435) were treated with
1 of 8 licensed ESA regimens. Of these, 9486
participants received epoetin alfa (16 studies
contributing 17 treatment arms25,28–31,34–44), 1177
received epoetin beta (3 studies contributing 3 treat-
ment arms26,45,46), 216 received epoetin zeta (1 study
contributing 1 treatment arm47), and 1149 received
darbepoetin alfa (4 studies contributing 5 treatment
arms27,48–50). The predominant epoetin alfa regimen
was 40,000 IU weekly (13 studies28–31,34–38,42,43,51),
and 3 epoetin alfa studies used 30,000 IU
weekly.25,39,44 Of the 3 studies using epoetin beta, 2
administered 30,000 IU weekly26,46 and the remaining
study45 used the weight-based dosing schedule of 450
IU/kg/wk. The only study including epoetin zeta47
used 1 of 2 weight-based dosing regimens (either
150 IU/kg TIW or 450 IU/kg/wk). Two of the 4Volume 36 Number 4
Searches
Title/Abstract Screening
Full Paper/Report Screening
Records Retrieved
8909 records prior to de-duplication
Medline: 2513
Medline In-Process & Daily update: 98
Embase: 5756
Central: 313
Conference abstracts: 229
Total: 6687 records after deduplication 
Full Papers/Reports Assessed
Total: 363 records assessed
Studies Meeting Inclusion Criteria
Total: 61 papers reporting 55 studies (1 head-to head long versus short-
acting ESA RCT and 54 ESA arm studies)
Studies Considered to Represent the Highest Level of Evidence
(ie, Extracted And Analyzed Studies)
Head-to-head long versus short-acting ESA data: 1 RCT
ESA arm data: ESA arms from 24 studies (11 single-arm studies, 9 ESA vs. ESA
RCTs and 4 ESA vs placebo/control RCTs)
Mean weekly dose: 12 studies (Note: 1 study had 2 eligible ESA arms)
Dose adjustments: 20 studies (Note: two studies had two eligible ESA arms)
Excluded Records
(title/abstracts)
Excluded Records
Not relevant population: 11
Not relevant licensed ESA: 67
Not relevant outcome: 158
Not relevant study: 38
ESA type and dose NR: 20
Dose increases not permitted: 1
Unobtainable: 7
Note: Studies may be excluded for more than
one reason
Total: 302 records excluded
(Full papers)
Figure 1. Summary of study selection process. ESA ¼ erythropoiesis-stimulating agent, NR ¼ not reported,
RCT ¼ randomized controlled trial.
C.A. Forbes et al.darbepoetin alfa studies adopted the 500 mg Q3W
regimen,49,50 and 1, the more frequent dosing regimen
of 2.25 mg/kg/wk48; 1 study allowed either regimen.27
Approximately half of the studies included patients
with solid tumors,25,26,28–31,34,36,38,39,41,42,43 and the
remainder included those with either solid or hema-
tologic tumors.27,33,35,37,40,43,44,46,48–50,52 WhereApril 2014reported, the types of antitumor therapies adminis-
tered during the studies were a mixture of platinum-
based and non–platinum-based regimens. Four
studies used only platinum-based regimens,25,28,39,45
and 2 studies used only non–platinum-based
regimens.26,29 In 7 of the 25 included studies, addi-
tional anticancer therapies were used, including599
Table II. Characteristics of the studies included in the analysis.* Values are number (%) of studies.
Characteristic
Long-Acting ESA
(Darbepoetin alfa) (n ¼ 5)
Short-Acting ESA
(n ¼ 21)
All Studies
(n ¼ 25)
Study design
RCT (ESA vs ESA) 4 (80) 7 (33) 10 (40)
Single-arm observational 1 (20) 10 (48) 11 (44)
RCT (ESA vs control/placebo) 0 4 (19) 4 (16)
Location
Europe 2 (40) 8 (38) 10 (40)
Worldwide multinational 2 (40) 1 (5) 3 (12)
US (and Canada, 1 study) 1 (20) 12 (57) 12 (48)
Cancer types included
Solid and hematologic 5 (100) 8 (38) 12 (48)
Solid 0 13 (62) 13 (52)
Speciﬁc tumor types included
Mixed tumor types 5 (100) 16 (76) 18 (72)
Lung cancer only (NSCLC and/or SCLC) 0 3 (14) 3 (12)
Breast cancer only 0 2 (10) 3 (12)
NR 0 1 (5) 1 (4)
Cancer therapy used
Chemo (plat and nonplat) 3 (60) 13 (62) 15 (60)
Chemo (type NR) 2 (40) 2 (10) 4 (16)
Chemo (plat) 0 4 (19) 4 (16)
Chemo (nonplat) 0 2 (10) 2 (8)
Additional cancer therapies used
Radiotherapy 0 1 (5) 3 (12)
Radio and surgery 0 1 (5) 1 (4)
Hormone therapy 0 0 1 (4)
Monoclonal antibody and hormone therapy 0 0 1 (4)
Baseline Hb, g/dL
o/r10 1 (20) 1 (5) 2 (8)
o/r10.5 1 (20) 2 (10) 2 (8)
o/r11 3 (60) 6 (29) 9 (36)
o/r12 0 4 (19) 4 (16)
o/r13 0 1 (5) 1 (4)
Other (including gender dependent) 0 6 (29) 6 (24)
NR 0 1 (5) 1 (4)
Target Hb, g/dL
NR 0 3 (14) 3 (12)
11 3 (60) 0 3 (12)
11–12 0 1 (5) 1 (4)
11–13 0 2 (10) 2 (8)
12 2 (40) 8 (38) 9 (36)
12–14 0 1 (5) 1 (4)
13 0 5 (29) 5 (20)
Other (including sex dependent) 0 1 (5) 1 (4)
ESA stopping rule
Stopped at Hb 412 g/dL, started Hb r11.5 g/dL 1 (20) 1 (5) 1 (4)
Stopped at Hb 413 g/dL, started Hb o/r12 g/dL 3 (60) 7 (33) 10 (40)
Stopped at Hb 414 g/dL, started Hb o/r13 g/dL 0 5 (29) 5 (20)
Stopped at Hb 415 g/dL, started Hb o/r13 g/dL 0 2 (10) 2 (8)
Other (including sex dependent) 1 (20) 2 (10) 3 (12)
NR 0 4 (19) 4 (16)
Iron supplementation allowed
Fixed (oral) 1 (20) 4 (19) 4 (16)
Fixed IV 1 (20) 0 1 (4)
Prn (IV) 0 3 (14) 3 (12)
Prn (IV or oral) 0 2 (10) 2 (8)
Prn (type NR) 0 2 (10) 2 (8)
(continued)
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Table II. (continued).
Characteristic
Long-Acting ESA
(Darbepoetin alfa) (n ¼ 5)
Short-Acting ESA
(n ¼ 21)
All Studies
(n ¼ 25)
Fixed (IV or oral) 0 1 (5) 1 (4)
NR 3 (60) 9 (43) 12 (48)
ESA regimen used
Epoetin alfa 30,000 IU/wk 0 2 (10) 2 (8)
Epoetin alfa 40,000 IU/wk 0 13 (62) 13 (52)
Epoetin alfa 150 IU/kg TIW 0 2 (10) 2 (8)
Epoetin beta 450 IU/kg/wk 0 1 (5) 1 (4)
Epoetin beta 30, 000 IU/wk 0 2 (10) 2 (8)
Epoetin zeta 150 IU/kg TIW or 450 IU/kg QW 0 1 (5) 1 (4)
Darbepoetin alfa 500 mg Q3W 5* (100) 0 4 (16)
Darbepoetin alfa 2.25 mg QW 2* (40) 0 2 (8)
RBCT use allowed/trigger
Mean/median r8 g/dL or Prn 2 (40) 0 2 (8)
Prn only 1 (20) 5 (24) 6 (24)
Mean/median r8 g/dL 1 (20) 5 (24) 6 (24)
Other 0 1 (5) 1 (4)
NR 1 (20) 10 (48) 10 (40)
Performance status
ECOG 0–1 0 1 (5) 1 (4)
ECOG 0–2 4 (80) 6 (29) 11 (44)
ECOG 0–3 0 3 (14) 3 (12)
ECOG 0–4 0 1 (5) 1 (4)
WHO 0–2 0 1 (5) 1 (4)
WHO 0–3 0 1 (5) 1 (4)
WHO 0–4 0 1 (5) 1 (4)
Karnofsky 51%–100% 0 1 (5) 1 (4)
NR 1 (20) 5 (24) 4 (16)
Chemo ¼ chemotherapy; ECOG ¼ Eastern Cooperative Oncology Group; ESA ¼ erythropoiesis-stimulating agent;
G-CSF ¼ granulocyte colony-stimulating factor; Hb ¼ hemoglobin; nonplat ¼ nonplatinum; NR ¼ not reported;
NSCLC ¼ non–small cell lung cancer; plat ¼ platinum; Prn ¼ as needed; radio ¼ radiotherapy; RBCT ¼ red
blood cell transfusion; RCT ¼ randomized controlled trial; SCLC ¼ small-cell lung cancer; WHO ¼ World Health
Organization.
*One study contributed 2 relevant ESA arms; granulocyte colony-stimulating factor use allowed was not reported in any of
the studies.
C.A. Forbes et al.radiotherapy,35,39,43 radiotherapy plus surgery,47
hormonal therapy,28 and monoclonal antibody plus
hormone therapy.48
The reported use of other concomitant anemia
therapies varied across the 25 studies and was often
poorly reported. None of the included studies clearly
stated whether granulocyte colony-stimulating factor
was used, and iron supplementation was only clearly
reported in 52% (13/25) of the studies. Four
studies reported the use of intravenous iron as
required,26,30,46,47 1 study recommended a ﬁxed
intravenous regimen,49 and 2 studies allowed
either intravenous or oral iron supplementation as
required.28,43April 2014Overall, the patients within the included studies
were representative of clinical practice and similar
across the darbepoetin alfa and short-acting ESA
groups. Where reported, the mean patient age ranged
from 50.4 years29 to 65.5 years,49 with the majority of
studies (23/25 [92%]) reporting a mean age within the
range of 60 to 65 years. Most studies included a
mixed population of both men and women, with the
exception of 3 studies that only included women—all
breast cancer patients.26,28,29 Mean baseline Hb
(where reported) ranged from 8.7 g/dL47 to 13.1 g/
dL.34 Ten studies used the current ESA stopping rule
(3 darbepoetin alfa studies and 7 short-acting ESA
studies). Mean serum ferritin levels at baseline were601
Clinical Therapeuticsreported in only 9 studies and ranged from 205 mg/L29
to 604 mg/L.26 A total of 20 studies reported the
performance status of study participants at baseline.
Of these, 16 studies25,27,28,30,31,34–37,39,42,43,45,48,49
used the Eastern Cooperative Oncology Group
(ECOG) performance status measure,50 3 used the
World Health Organization (WHO) measure,26,41,46
and 1 study used the Karnofsky scale.38 In the
majority of studies, participants with better perfor-
mance scores were included (ie, 0–1 for the ECOG
and WHO measures, and 80%–90% for the Karno-
fsky scale).
Methodological Quality
The only head-to-head trial (darbepoetin alfa ver-
sus short-acting ESA)33 used a randomized controlled
design, which places it in the highest level of the
design hierarchy in terms of answering the research
questions posed in this review. However, there was no
full publication available for this trial, and a quality
assessment of the abstract using the Downs and Black
quality assessment checklist suggested that the trial’s
methodological quality (or risk for bias) was unclear.
For the remaining 24 studies used in the ESA-arm
analysis, the methodological quality was variable and
no study completely fulﬁlled all of the applicable
criteria. All studies had some Downs and Black
criteria assessments which were considered as “un-
clear,” mainly due to the paucity of clearly reported
information in the text. In particular, the epoetin alfa
study by Harousseau et al44 had a large number of
responses that were judged to be “unclear,” primarily
due to data being available only in abstract form. Five
other studies had a large number of “no” or “unclear”Table III. Summary of dose efficiency results. Values are
Outcome Long-Acting ESA (
Mean weekly ESA dose 136.5 μg or 27,300 IU
Required a dose increase, % 0.75 (0
Required a dose decrease, % 74 (5
Required a dose to be withheld, % NC‡ (2
ESA ¼ erythropoiesis-stimulating agent; NC ¼ not calculated.
*Based on a 1:200 dose-conversion ratio to IU.14
†Pooled mean proportion requiring a dose increase reported as
‡Not calculated because only 2 studies were included.
602responses.35,41,43,45,46 Six studies appeared to be
at a lower risk for bias (ie, had fewer “no” and
“unclear” responses and fewer methodological
concerns).25–27,42,45,46
Dose-Efficiency Findings
The main dose-efﬁciency ﬁndings of the review are
summarized in Table III and Supplemental Tables I to
IV (in the online version at http://dx.doi.org/10.1016/
j.clinthera.2014.02.007).
Mean Weekly Dose
There were no head-to-head (darbepoetin alfa vs
short-acting ESA) studies reporting mean weekly ESA
dose. However, data from 13 ESA arms (5 darbepoetin
alfa27,48–50 and 8 short-acting ESA arms28,30,36–40,47)
were available (see Supplemental Table I in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.
02.007). One study27 contributed 2 eligible darbe-
poetin alfa arms (500 mg Q3W and 2.25 mg/kg/wk)
to the analysis (see Supplemental Table I in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.
02.007).
Figure 2A shows the forest plot of mean weekly
dose, grouped by ESA type. The levels of hetero-
geneity between studies (I2) were high, at 98% (short-
acting ESAs) and 99% (darbepoetin alfa); hence,
statistical pooling was not performed. Instead, the
median (range) of the mean values reported for each
individual study was calculated. For the 8 short-acting
ESA studies, the median was 38,230 IU (range,
31,634–42,714 IU), whereas for the 4 darbepoetin
alfa studies, the median weekly value was 136.5 μg or
27,300 IU (range, 21,560–38,260 IU), suggesting thatmedian (range).
Darbepoetin alfa) Short-Acting ESA
* (21,560–38,260 IU) 38,230 IU (31,634–42,714 IU)
–1.84)† 26.6 (7.6–44.6)
7–75) 22 (2.8–59)
0–33) 33.2 (13–51)
heterogeneity was low (I2 ¼ 21%).
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required target Hb with darbepoetin alfa. Mean
weekly doses appeared 30% lower in patients
receiving darbepoetin alfa compared with patients
receiving short-acting ESAs, resulting in mean weekly
dose ratio 1:280.Dose Increases
There were no head-to-head (darbepoetin alfa vs
short-acting ESA) studies reporting the number of
dose increases required. However, data from 18 ESA
arms (2 darbepoetin alfa48,49 and 16 short-acting
ESA arms25,26,28–31,34–36,41–46) were available (see
Supplemental Table II in the online version at http://
dx.doi.org/10.1016/j.clinthera.2014.02.007). One
study34 contributed 2 eligible short-acting ESA arms
to the analysis (see Supplemental Table II in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.
02.007).
Figure 2B shows the forest plot of the percentage of
patients requiring a dose increase. The 2 studies of
long-acting ESAs (darbepoetin alfa) reported similar
percentages of patients and the heterogeneity between
the studies was low (I2 ¼ 21%), which allowed
statistical pooling. The pooled proportion was
0.75% (95% CI, 0%–1.84%). The studies of short-
acting ESAs showed high statistical heterogeneity
(I2 ¼ 97%) and therefore statistical pooling was not
performed. The median percentage of patients requir-
ing a dose increase with short-acting drugs was 26.6%
(range, 7.6%–44.6%), suggesting a dose saving with
darbepoetin alfa (ie, fewer patients receiving darbe-
poetin alfa received a dose increase compared with
those patients receiving short-acting ESAs).Dose Decreases
There were no head-to-head (darbepoetin alfa vs
short-acting ESA) studies reporting the number of
dose decreases required. However, data from 12 ESA
arms (3 darbepoetin alfa27,49 and 9 short-acting ESA
arms26,28,30,31,34,36,45,46) were available (see
Supplemental Table III in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.02.007).
One study34 contributed 2 eligible short-acting ESA
arms to the analysis, and 1 study contributed 2 eligible
darbepoetin alfa arms (see Supplemental Table III
in the online version at http://dx.doi.org/10.1016/j.
clinthera.2014.02.007).27April 2014Figure 2C shows the forest plot of the percentages
of patients requiring a dose decrease. High levels of
statistical heterogeneity were observed for both the
long-acting ESAs (darbepoetin alfa; I2 ¼ 85%) and
short-acting ESAs (I2 ¼ 99%); therefore, statistical
pooling was not performed. The median for darbe-
poetin alfa was 74% (range, 57%–75%) compared
with 22% (range, 2.8%–59%) for short-acting ESAs,
suggesting a dose saving with darbepoetin alfa (ie,
more patients receiving darbepoetin alfa required a
dose decrease compared with those patients receiving
short-acting ESAs).
Doses Withheld
The RCT by Steensma et al33 directly compared
darbepoetin alfa and a short-acting ESA, with respect to
the number of participants requiring an ESA dose to be
withheld. Due to the unclear risk for bias within that
study, which was reported only as a conference ab-
stract, and because the numbers of participants in each
treatment arm were not available, we were unable to
assess relative strength of the observations and do not
report the results further. However, details are available
in Supplemental Table IV in the online version at http://
dx.doi.org/10.1016/j.clinthera.2014.02.007.
Data were also available from 6 ESA arms (2
darbepoetin alfa arms48,49 and 4 short-acting ESA
arms31,36,40,45) (Figure 2D and Supplemental Table IV
in the online version at http://dx.doi.org/10.1016/j.
clinthera.2014.02.007). The results show high stati-
stical heterogeneity for the long-acting drug (darbepoe-
tin alfa; I2 ¼ 89%) and the short-acting drugs (I2 ¼
97%); therefore, statistical pooling was not performed.
Instead, the median (range) of values was calculated.
Only 2 darbepoetin alfa studies reported the percentage
with dose withheld (20%48 and 33%49). The median
percentage with the short-acting drugs was 33.2%
(range, 12.6%–51.1%), which suggests similar results
with both darbepoetin alfa and short-acting ESAs.
Subgroup Analyses
To further investigate potential sources of hetero-
geneity for each outcome, subgroup analyses were
performed by grouping studies according to ESA drug
(epoetin alfa, epoetin alfa biosimilar, epoetin zeta,
epoetin beta, and epoetin theta), iron administration,
baseline Hb level, target Hb level, Hb stopping
rule, year of study (ie, pre- versus post-stopping
rule introduced in 2006),32 tumor type, and603
Mean
IV, Random, 95% CIStudy or Subgroup Mean SE Weight, %
Short-acting ESA
Glaspy 1997 35.59 0.55 12.7 35.59 (34.51 to 36.67) 
Glaspy 2006 
Henry 2006 
Hudis 2005 
Milroy 2011 
42.71 0.35 12.9 42.71 (42.02 to 43.40)
39.35 0.73 12.5 39.35 (37.92 to 40.78)
37.16 0.23 13.0 37.16 (36.71 to 37.61)
31.63 0.59 12.7 31.63 (30.47 to 32.79)
Schwartzberg 2004 39.95 1.00 12.1 39.95 (37.99 to 41.91)
Tzekova 2009 38.42 1.28 11.5 38.42 (35.91 to 40.93)
Waltzman 2005 38.04 0.66 12.6 38.04 (36.75 to 39.33)
Subtotal (95% CI) 100.0 37.84 (35.38 to 40.30)
Heterogeneity: τ2 = 12.06; χ2 = 337.50, df = 7 (P < 0.00001); I2 = 98%
Test for overall effect: Z = 30.16 (P < 0.00001)
Long-acting ESA (Darbepoetin alfa)
Canon 2006 
Canon 2006 
Eisterer 2011 
Kotasek 2007 
Auerbach 2010 27.30 0.62 20.0 27.30 (26.08 to 28.52)
21.56 0.45 20.1 21.56 (20.68 to 22.44)
25.04 0.39 20.1 25.04 (24.28 to 25.80)
32.38 0.54 20.0 32.38 (31.32 to 33.44)
38.26 0.79 19.8 38.26 (36.71 to 39.81)
Subtotal (95% CI) 100.0 28.88 (23.87 to 33.89)
Heterogeneity: τ2 = 32.37; χ2 = 473.73, df = 4 (P < 0.00001); I2 = 99%
Test for overall effect: Z = 11.29 (P < 0.00001)
Canon 2006 had 2 relevant darbepoetin alfa arms (500 µg Q3W
and 2.25 µg QW)
–50 –25 0 25 50
–50 –25 0 25 50
Mean
IV, Random, 95% CI
Mean
IV, Random, 95% CIStudy or Subgroup Percentage SE Weight, %
Short-acting ESA
Aapro 2008 44.6 3.27 6.1 44.60 (38.19 to 51.01)
Biesma 2007 
Carteni 2007 
Chang 2005 
Crawford 2007 (delayed)
Crawford 2007 (immediate)
de Castro 2007 
Gabrilove 2001 
Granetto 2003 
Harousseau 2005 
Henry 2006 
Hudis 2005 
Shasha 2003 
Spaeth 2010 
Waltzman 2005 
Witzig 2005 
7.6 1.43 6.6 7.60 (4.80 to 10.40)
11.1 1.43 6.6 11.10 (8.30 to 13.90)
9.2 2.18 6.4 9.20 (4.93 to 13.47)
29.2 6.56 4.9 29.20 (16.34 to 42.06)
20.8 3.91 5.9 20.80 (13.14 to 28.46)
20.8 2.54 6.3 20.80 (15.82 to 25.78)
33.4 0.87 6.6 33.40 (31.69 to 35.11)
14.0 2.14 6.4 14.00 (9.81 to 18.19)
33.6 1.61 6.5 33.60 (30.44 to 36.76)
37.0 4.01 5.9 37.00 (29.14 to 44.86)
22.0 1.03 6.6 22.00 (19.98 to 24.02)
34.8 2.27 6.4 34.80 (30.35 to 39.25)
24.0 1.63 6.5 24.00 (20.81 to 27.19)
44.0 3.72 6.0 44.00 (36.71 to 51.29)
42.8 3.84 6.0 42.80 (35.27 to 50.33)
Subtotal (95% CI) 100.0 26.51 (20.89 to 32.13)
Heterogeneity: τ2 = 122.97; χ2 = 565.01, df = 15 (P < 0.00001); I2 = 97%
Test for overall effect: Z = 9.25 (P < 0.00001)
Long-acting ESA (Darbepoetin alfa)
Auerbach 2010 
Kotasek 2007 
Subtotal (95% CI) 
2.0 1.28 16.6 2.00 (–0.51 to 4.51)
0.5 0.37 83.4 0.50 (–0.23 to 1.23)
100.0 0.75 (–0.35 to 1.84)
Heterogeneity: τ2 = 0.24; χ2 = 1.27, df = 1 (P = 0.26); I2 = 21%
Test for overall effect: Z = 1.34 (P = 0.18)
Crawford 2007 (delayed) – epoetin alfa 40,000 U weekly initiated only when hemoglobin
fell to ≤10 g/dL during chemotherapy
Crawford 2007 (immediate) - epoetin alfa 40,000 U weekly initiated at the start of chemotherapy
Mean
IV, Random, 95% CI
Figure 2. Forest plots showing (A) mean (95% CIs) weekly doses (per 1000 IU); and percentages (95% CIs) of
patients requiring a dose (B) increase, (C) decrease, or (D) withheld, by erythropoiesis-stimulating
agent (ESA) type (ESA-arm data). IV ¼ inverse variance.
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Mean
IV, Random, 95% CI
Mean
IV, Random, 95% CIStudy or Subgroup Percentage SE Weight, %
Short-acting ESA
Aapro 2008 
Carteni 2007 
de Castro 2007
Henry 2006 
Hudis 2005 
Spaeth 2010 
Waltzman 2005 
Subtotal (95% CI) 
27.3 2.93 11.1 27.30 (21.56 to 33.04)
10.7 1.40 11.2 10.70 (7.96 to 13.44)
Crawford 2007 (delayed) 4.2 2.90 11.1 4.20 (–1.48 to 9.88)
Crawford 2007 (immediate) 11.3 3.05 11.1 11.30 (5.32 to 17.28)
2.75 1.02 11.2 2.75 (0.75 to 4.75)
59.0 4.08 10.9 59.00 (51.00 to 67.00)
53.0 1.24 11.2 53.00 (50.57 to 55.43)
22.0 1.58 11.2 22.00 (18.90 to 25.10)
42.0 3.70 11.0 42.00 (34.75 to 49.25)
100.0 25.71 (10.98 to 40.44)
Heterogeneity: τ2 = 501.47; χ2 = 1207.89, df = 8 (P < 0.00001); I2 = 99%
Test for overall effect: Z = 3.42 (P < 0.0006)
Long-acting ESA (Darbepoetin alfa)
Auerbach 2010 
Canon 2006 
Canon 2006 
Subtotal (95% CI) 
57.0 4.52 27.8 57.00 (48.14 to 65.86)
75.0 2.31 36.1 75.00 (70.47 to 79.53)
74.0 2.33 36.1 74.00 (69.43 to 78.57)
100.0 69.63 (61.25 to 78.01)
Heterogeneity: τ2 = 45.26; χ2 = 13.34, df = 2 (P = 0.001); I2 = 85%
Test for overall effect: Z = 16.29 (P < 0.00001)
Canon 2006 had 2 relevant darbepoetin alfa arms (500 µg Q3W 
and 2.25 µg QW)
Crawford 2007 (delayed) – epoetin alfa 40,000 U weekly initiated only when 
hemoglobin fell to ≤10 g/dL during chemotherapy
Crawford 2007 (immediate) - epoetin alfa 40,000 U weekly initiated at the start of chemotherapy
–100 –50 0 50 100
Mean
IV, Random, 95% CI
Mean
IV, Random, 95% CIStudy or Subgroup Percentage SE Weight, %
Short-acting ESA
Carteni 2007 
de Castro 2007 
Glaspy 1997 
Henry 2006 
24.3 1.95 25.5 24.30 (20.48 to 28.12)
12.6 2.08 25.4 12.60 (8.52 to 16.68)
51.1 3.28 24.8 51.10 (44.67 to 57.53)
42.0 4.10 24.3 42.00 (33.96 to 50.04)
Subtotal (95% CI) 100.0 32.27 (16.27 to 48.27)
Heterogeneity: τ2 = 257.80; χ2 = 115.95, df = 3 (P < 0.00001); I2 = 97%
Test for overall effect: Z = 3.95 (P < 0.0001)
Long-acting ESA (Darbepoetin alfa)
Auerbach 2010 
Kotasek 2007 
20.0 3.65 47.8 20.00 (12.85 to 27.15)
33.0 2.41 52.2 33.00 (28.28 to 37.72)
Subtotal (95% CI) 100.0 26.79 (14.06 to 39.52)
Heterogeneity: τ2 = 74.93; χ2 = 8.83, df = 1 (P = 0.003); I2 = 89%
Test for overall effect: Z = 4.13 (P < 0.0001)
–100 –50 0 50 100
Figure 2. (continued)
C.A. Forbes et al.chemotherapy regimen. Grouping the studies by these
factors did not reduce the observed heterogeneity in
the majority of cases, and no obvious trends in the
data were observed. Grouping studies according to the
current ESA stopping rule reduced the level of
statistical heterogeneity when pooling the studies
reporting dose increases and doses withheld.April 2014For dose increases, heterogeneity (I2) was reduced
from 97% to 64% in the short-acting ESA group,
allowing pooling to be performed. This resulted in a
pooled result of 36.2% (95% CI, 32.3%–40.1%)
compared with 0.75% (95% CI, 0%–1.84%) with
darbepoetin alfa. This ﬁnding was in agreement with
the initial ﬁnding that fewer darbepoetin alfa patients605
Clinical Therapeuticsrequire a dose increase compared with short-acting
ESA patients. For doses withheld, heterogeneity de-
creased from 97% to 67% in the short-acting ESA
group, allowing the pooling of 2 short-acting ESA
studies.40,53 The pooled proportion was 46.9% (95%
CI, 38.0%–55.8%) compared with a range of 20% to
33% for the darbepoetin alfa studies,48,49 suggesting
more doses withheld with short-acting ESAs.
DISCUSSION
In these analyses, the mean weekly ESA doses ap-
peared to be 30% lower for the 4 darbepoetin alfa
studies27,48–50 (median, 27,300 IU) compared with the
8 short-acting ESA studies28,30,36–40,47 (median,
38,230 IU). In addition, patients receiving darbepoetin
alfa (2 studies48,49) appeared to need fewer dose
increases (pooled value, 0.75% [95% CI, 0%–
1.84%]) than patients receiving short-acting ESAs
(15 studies25,26,28–31,34–36,41–46; median, 26.6%). Dar-
bepoetin alfa patients (3 arms from 2 studies27,49) also
appeared to require more dose decreases (median,
74%) than patients receiving short-acting ESAs
(9 studies26,28,30,31,34,36,45,46; median, 22%). The
numbers of doses withheld appeared to be similar
based on 2 darbepoetin alfa studies and 4 short-acting
ESA studies (20% and 30% for the 2 darbepoetin alfa
studies48,49 compared with a median of 33.2% for the
4 short-acting ESA studies31,36,40,45).
In line with the trends observed in our study, a
review by Bonafont et al16 has evaluated the potential
dose savings associated with changing from short-
acting ESAs to darbepoetin alfa in nephrology patients
undergoing dialysis. This included prospective compa-
rative studies (randomized, nonrandomized, and ob-
servational studies), together with single-arm studies in
which the ESA was “switched” between short-acting
agents and darbepoetin alfa. The authors reported that,
using the 200:1 starting dose conversion indicated by
the EMEA in the prescribing label,14 the conversion
from epoetin to darbepoetin alfa was associated with
an average 30% dose savings,16 which corresponds
with the ﬁndings of the present review.
Research on the use of darbepoetin alfa in patients
with CIA in clinical practice has also suggested that
using this agent may lead to dose savings and a
reduction in costs.15 For example, results from a
retrospective database study in Belgian hospitals15
showed that patients receiving darbepoetin alfa were
administered smaller amounts of ESA compared with606those receiving epoetin alfa, but had similar clinical
outcomes. The authors concluded that darbepoetin alfa
was more efﬁcient than was epoetin alfa, and was
associated with a reduction in both in drug and total
health care costs.15 Other research in patients with CIA
has suggested that alternative dose-conversion ratios
would be more appropriate. Research by Berger et al,54
using 2 large US health care claims databases, suggested
that the mean weekly epoetin alfa/darbepoetin alfa dose
ratio has been reduced in patients with CIA to between
1:306 and 1:340, favoring darbepoetin alfa. The
authors reported that this was due, at least in part, to
the availability and use of the new dose/dosing schedule
for darbepoetin alfa (once every 3 weeks), without
similar changes for epoetin alfa.54 However, research
from other investigators, including Gosselin et al55 and
a systematic review and meta-analysis by Rosberg
et al,12 did not report dose savings with darbepoetin
alfa. This may be due to the age of the research, because
no stopping rule and older dosing regimens were used
and not all administration schedules were available at
the time (eg, darbepoetin alfa every 3 weeks).
Overall, taking into account all of the evidence, our
review suggests that darbepoetin alfa could offer dose
savings over short-acting ESAs. However, caution is
advised. A meta-analysis comparing darbepoetin alfa
versus short-acting ESAs was not possible due to the
lack of head-to-head studies; only 1 study (reported as
an abstract) directly compared darbepoetin alfa and
short-acting ESAs. The ﬁndings of this review are
therefore based on comparisons of medians and
ranges from ESA-arm data, which showed consider-
able variation and should be treated with caution.
Strengths and Limitations of the Review
The strengths of the review include the adherence to
accepted rigorous standards for the conduct of systematic
reviews, and the use of extensive literature searches to
identify relevant data. The review includes a well-deﬁned
group of studies, in which ESA doses were administered
only in accordance with the current EMA labels. Con-
sideration was also given to the baseline and target Hb
levels used and to the ESA stopping rule applied,
although this was not always clearly reported in the
publications and differed by the date of the study. All of
these factors may inﬂuence the need for dose adjustments.
Given the lack of head-to-head (darbepoetin alfa vs short-
acting ESA) studies eligible for inclusion, ESA-arm data
were also included to allow an assessment to be made,Volume 36 Number 4
C.A. Forbes et al.based on the best available evidence. One of the strengths
of the review, in this respect, was the application of a
hierarchy of evidence. Given the reliance on ESA-arm
data, the hierarchy ensured that the analysis was based
only on the best available evidence, that is, data were
prospective and based on a reasonably sized sample of
patients (Z100 patients per ESA arm), and all patients
complied with the licensed dose as planned. However,
this resulted in the exclusion of some studies, such as a
pivotal trial of epoetin theta,56 which included 76
participants receiving epoetin theta, 73 receiving epoetin
beta, and 74 receiving placebo. Due to an overall dose-
per-week average, the inclusion of that trial or any other
lower-quality evidence in the analysis would be unlikely
to reduce the high level of statistical heterogeneity
observed and so would not have altered the conclusions
of this review. When estimating the dose efﬁciency of the
studies, the review also did not take into account the
differences in the biological half-life of darbepoetin alfa
compared with that of the short-acting ESAs, which
means that the effects of darbepoetin alfa will go on for
longer after the last administration of the drug,14 and
hence the actual dose efﬁciency of darbepoetin alfa in our
ﬁndings could have been underestimated.
Another strength of this review was that the clinical
and patient characteristics were representative of
patients seen in clinical practice and were similar
among the short-acting ESA and the darbepoetin alfa
study groups. Subgrouping according to ESA drug,
iron administration, baseline Hb level, target Hb level,
tumor type, and chemotherapy regimen did not alter
the ﬁndings of the review or reduce the levels of
statistical heterogeneity. However, restricting the anal-
ysis of dose increases and doses withheld to only those
studies complying with the current recommended ESA
stopping rule reduced the level of heterogeneity. This
allowed the statistical pooling of the studies, but again
did not alter the overall ﬁndings of the review. Despite
the application of rigorous methods to reduce and/or
control the risk of bias and error as assessed by the
criteria of Downs and Black for observational studies,
this review cannot be completely free of potential
biases or errors beyond our control. The main
limitations faced during the conduct of this review
were the poor reporting of studies and their often
limited methodological rigor (eg, lack of control
groups, lack of randomization and blinding, and small
sample size). In particular, studies often failed to
report details of any iron supplementation used andApril 2014the route of administration, whether the administra-
tion of granulocyte colony-stimulating factor was
allowed, and under what circumstances (if any)
RBCTs were permitted. These are all standard co-
therapies for the treatment of anemia and may
inﬂuence the effects of ESA treatments and, poten-
tially, the need for dose adjustments.
The other main limitations of this review centered
on the analysis. Our study did not consider costs;
hence, a cost for effect achieved comparison was not
possible. It was also difﬁcult to make reliable and
rigorous conclusions based on the evidence available,
primarily due to the lack of studies directly comparing
darbepoetin alfa and short-acting ESAs, but also
because of the statistical heterogeneity between the
included studies. Often the ranges of the results were
wide, again indicating the high level of variability
between studies. Furthermore, in many cases it was
not clear from the studies why dose adjustments were
made, and so the outcomes measured may not have
been comparable. In addition, our analysis does not
take into account the greater potential for dose adjust-
ments to occur with the administration of short-acting
ESAs compared with darbepoetin alfa. Given that
short-acting ESAs are usually administered more fre-
quently than is darbepoetin alfa, there is a greater risk
for dose increases, decreases, or withholding. With
respect to the mean dose, it was not always clear
whether the mean doses applied across the whole
treatment period or the ﬁnal period or were based on
the dosages required to achieve the target Hb level.
Given the ﬁndings of this review, further large-scale,
well-conducted, prospective studies are required to di-
rectly compare the dose outcomes of darbepoetin alfa and
short-acting ESAs. These studies should clearly report
baseline patient characteristics, study methods, and out-
comes in accordance with the relevant reporting standards
(ie, STROBE [Strengthening the Reporting of Observa-
tional studies in Epidemiology; http://www.strobe-state
ment.org/ and CONSORT [Consolidated Standards Of
Reporting Trials]; http://www.consort-statement.org/).
CONCLUSIONS
Good-quality, reliable data from head-to-head trials
of darbepoetin alfa and short-acting ESAs are lacking,
and prospective ESA-arm data currently represent the
best available evidence. This review suggests a dose
efﬁciency of darbepoetin alfa compared with short-
acting ESAs, when considering mean weekly doses,607
Clinical Therapeuticsdose increases, and dose decreases. However, the
amount of variation between the study results was
high, precluding meta-analysis for most outcomes.
Without studies directly comparing darbepoetin alfa
and short-acting ESAs, these ﬁndings are tentative and
future research is warranted in this important area.
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Supplemental Table I. Summary of studies included in the mean weekly dose analysis.
Author and
year
ESA brand
name
Total no.
of pts
receiving
ESAs, N
Starting
dose
Mean
baseline
Hb, g/dL
Mean
baseline
age (SD),
years Iron
Tumour
type Chemotherapy
Actual treatment
duration, wks
MWD
reported/
calculated
MWD (SD)
original
units
MWD (SD)
Converted
to IU*
Short-acting: epoetin A
Henry 200636 Epoetin alfa
(brand NR)
145 40,000 IU/wk 9.9 60.9 (12.5) Fixed oral Solid Chemo (plat þ
non-plat)
Mean 8.7 Calculated 39346 (NR) 39346 (NR)
Glaspy 200637 Procrits 598 40,000 IU/wk 10.2 63.7 (11.6) NR Solid þ
haem
Chemo (plat þ
non-plat)
Mean 12.3, max 16 Reported 42714 (8645) 42714 (8645)
Waltzman 200530 Procrits 178 40,000 IU/wk 10.16 62.1 (NR) i.v. prn Solid Chemo (plat þ
non-plat)
Mean 11 Calculated 38043.6 (NR) 38043.6 (NR)
Hudis 200528 Epoetin alfa
(brand NR)
1632 40,000 IU/wk 12.3 53 (10.7) i.v or oral
prn
Solid Chemo (plat) Mean NR. 12-24 wks Reported 37155 (9368) 37155 (9368)
Schwartzberg
200438
Procrits 155 40,000 IU/wk 10.4 61.7 (12.1) NR Solid Chemo (plat þ
non-plat)
Mean 12.8 (SD 4.4),
16 planned
Reported 39949 (12503) 39949 (12503)
Milroy 201139 Eprexs 189 30,000 IU/wk 12.8 61.6 (8.7) NR Solid Chemo (plat) Mean 10.24 (SD
6.4)
Reported 31634.4 (8082.9) 31634.4 (8083)
Glaspy 199740 Procrits 233 150 IU/kg TIW 9.3 62.1 (13.4) NR Solid þ
haem
Chemo (plat þ
non-plat)
17.3 (only those
completing
4 mths included)
Reported 508.4 (120.9) 35588 (8463)
Short-acting: epoetin zeta
Tzekova 200947 Retacrits 216 150 IU/kg TIW
or 450 IU/
kg QW
8.7 60 (NR) Fixed i.v. or
oral
Solid þ
haem
Chemo (NR) þ
radio þ
surgery
11 Reported 548.8 (269.4) 38416 (18858)
Long-acting: darbepoetin A
Eisterer 201150 Aranesps 309 500 mg Q3W 10 62 (13) NR Solid þ
haem
Chemo (plat þ
non-plat)
Mean: 13.7 (SD 4.8) Calculated 161.9 (NR) 32380 (NR)
Auerbach 201049 Aranesps 120 500 mg Q3W 9.3 65.5 (13) Fixed i.v. Solid þ
haem
Chemo (plat þ
non-plat)
11.3 Reported 136.5 (33.9) 27300 (6780)
Kotasek 200748 Aranesps 367 2.25 mg QW 9.6 61.9 (NR) NR Solid þ
haem
Chemo (NR) 16 Reported 191.3 (75.8) 38260 (15160)
Canon 200627 Aranesps 353 500 mg Q3W 9.76 58.7 (13.1) NR Solid þ
haem
Chemo (NR) Mean 12.8 (SD 3.6) Reported 125.2 (37.1) 25040 (7420)
Aranesps 352 2.25 mg QW 9.78 59.3 (12.3) NR Solid þ
haem
Chemo (NR) Mean 12.3 (SD 3.9) Reported 107.8 (42.2) 21560 (8440)
Chemo ¼ chemotherapy; ESA ¼ erythropoiesis-stimulating agent; haem ¼ haematological cancers; Hb ¼ haemoglobin; MWD ¼ mean weekly dose; non-plat ¼
non-platinum based; plat ¼ platinum based; pts ¼ patients; SD ¼ standard deviation; NR ¼ not reported; i.v. ¼ intravenous; QW ¼ every week; Q3W ¼ every 3
weeks; prn ¼ as required; TIW ¼ three times a week; wk ¼ week.
*To convert to IU weight based doses were either multiplied by mean patient weight in kg (if reported) or a mean weight of 70 kg. This was also applied to weight-
based doses of darbepoetin A and they were then multiplied by 200 to convert to IU (as reported in Aranesp Summary of Product Characteristics)
†Contributed two ESA arms.
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4Supplemental Table II. Summary of studies included in the dose increase analysis.
al
T
h
erapAuthor and year
ESA brand
name
Starting
dose
Mean
baseline
Hb, g/dL
Mean baseline
age (SD),
years Iron Tumour Chemotherapy
Actual treatment
duration, wks
No. pts. with
ESA dose
increase, n
Total no.
of pts receiving
ESA, N
% pts.
with dose
increase (SE)
Short-acting: epoetin A
Biesma 200741 Epoetin alfa
(brand NR)
40,000 IU/wk 10.6 61.2 (9.1) NR Solid Chemo (plat þ non-plat) 4 to 12 26 343 7.6 (1.43)
Carteni 200731 Eprexs 40,000 IU/wk 10.43 60.1 (11.0) NR Solid Chemo (plat þ non-plat) 12 54 485 11.1 (1.43)
Crawford 200734þ Epoetin alfa
(brand NR)
40,000 IU/wk* 13.1 62.3 (11.0) NR Solid Chemo (plat þ non-plat) 10.6 (mean chemo
duration)
22 108 20.8 (3.91)
Epoetin alfa
(brand NR)
40,000 IU/wk** 13 62.7 (10.6) NR Solid Chemo (plat þ non-plat) 10.6 (mean chemo
duration)
14 48 29.2 (6.56)
Henry 200636 Epoetin alfa
(brand NR)
40,000 IU/wk 9.9 60.9 (12.5) Fixed oral Solid Chemo (plat þ non-plat) Mean 8.7 54 145 37 (4.01)
Waltzman 200530 Procrits 40,000 IU/wk 10.16 62.1 (NR) i.v. prn Solid Chemo (plat þ non-plat) Mean 11 78 178 44 (3.72)
Hudis 200528 Epoetin alfa
(brand NR)
40,000 IU/wk 12.3 53 (10.7) i.v. or oral
prn
Solid Chemo (plat) 12 to 24 357 1622 22 (1.03)
Chang 200529 Epoetin alfa
(brand NR)
40,000 IU/wk 11.2 50.4 (11.1) Fixed oral Solid Chemo (non-plat) 16 to 28 16 175 9.2 (2.18)
Witzig 200542 Epoetin alfa
(brand NR)
40,000 IU/wk 9.5 63.6 (11.9) Fixed oral Solid Chemo (plat þ non-plat) 16 71 166 42.8 (3.84)
Granetto 200325 Eprexs 150 IU/kg TIW 9.65 61.1 (10.0) iron prn
(type NR)
Solid Chemo (plat) 12 (planned) 37 264 14 (2.14)
Shasha 200343 Procrits 40,000 IU/wk 9.9 61.7 (NR) i.v or oral
prn
Solid þ haem Chemo (plat þ non-plat)
þradio
16 154 442 34.8 (2.27)
Gabrilove 200135 Epoetin alfa
(brand NR)
40,000 IU/wk 9.5 63.1 (12.8) NR Solid þ haem Chemo (plat þ non-plat) 16 990 2964 33.4 (0.87)
Harousseau 200544 Epoetin alfa
(brand NR)
30,000 IU/wk 9.6 NR (NR) NR Solid þ haem Chemo (NR) Max 28 288 858 33.6 (1.61)
Short-acting: epoetin B
Spaeth 201046 NeoRecormons 30,000 IU/wk 10.1 65 (NR) i.v. prn Solid þ haem Chemo (plat þ non-plat) Median 14.2 (SD
4.9)
166 691 24 (1.63)
Aapro 200826 NeoRecormons 30,000 IU/wk 11.5 56.0 (27-78)# i.v. prn Solid Chemo (non-plat) 24 103 231 44.6 (3.27)
de Castro 200745 NeoRecormons 450 IU/kg/wk 10.8 61 (19-91)# iron prn
(type NR)
Solid Chemo (plat) Median 9.9 53 255 20.8 (2.54)
Long-acting: darbepoetin A
Auerbach 201049 Aranesps 500 mg Q3W 9.3 65.5 (13) Fixed i.v. Solid þ haem Chemo (plat þ non-plat) 11.3 2 120 2 (1.28)
Kotasek 200748 Aranesps 2.25mg QW 9.6 61.9 (NR) NR Solid þ haem Chemo (NR) 16 2 367 0.5 (0.37)
Chemo ¼ chemotherapy; haem ¼ haematological cancers; Hb ¼ haemoglobin; i.v. ¼ intravenous; non-plat ¼ non-platinum based; NR ¼ not reported; plat ¼
platinum based; prn ¼ as required; pts ¼ patients; QW ¼ every week; Q3W ¼ every 3 weeks; SD ¼ standard deviation; SE ¼ standard error; TIW ¼ three times per
week; wk ¼ week.
*Immediate treatment group
†Contributed two ESA arms
**Delayed treatment group
#Median (range) reported.
eu
tics
Supplemental Table III. Summary of studies included in the dose decrease analysis.
Author and year
ESA brand
name
Starting
dose
Mean
baseline
Hb, g/dL
Mean
baseline age
(SD), years Iron Tumour Chemotherapy
Actual treatment
duration, wks
No. pts.
with ESA
dose
decrease, n
Total no.
of pts
receiving
ESA, N
% pts. with
dose
decrease
(SE)
Short-acting: epoetin A
Carteni 200731 Eprexs 40,000 IU/wk 10.43 60.1 (11.0) NR Solid Chemo (plat þ
non-plat)
12 52 485 10.7 (1.4)
Crawford 200734† Epoetin alfa (brand
NR)
40,000 IU/
wk*
13.1 62.3 (11.0) NR Solid Chemo (plat þ
non-plat)
10.6 (mean chemo
duration)
12 108 11.3 (3.05)
Epoetin alfa (brand
NR)
40,000 IU/
wk**
13 62.7 (10.6) NR Solid Chemo (plat þ
non-plat)
10.6 (mean chemo
duration)
2 48 4.2 (2.9)
Henry 200636 Epoetin alfa (brand
NR)
40,000 IU/wk 9.9 60.9 (12.5) Fixed oral Solid Chemo (plat þ
non-plat)
Mean 8.7 86 145 59 (4.08)
Waltzman 200530 Procrits 40,000 IU/wk 10.16 62.1 i.v. prn Solid Chemo (plat þ
non-plat)
Mean 11 75 178 42 (3.7)
Hudis 200528 Epoetin alfa (brand
NR)
40,000 IU/wk 12.3 53 (10.7) i.v. or oral
prn
Solid Chemo (plat) 12 to 24 861 1622 53 (1.24)
Short-acting: epoetin B
Spaeth 201046 NeoRecormons 30,000 IU/wk 10.1 65 (17-89)# i.v. prn Solid þ haem Chemo (plat þ
non-plat)
Median 14.2 (SD
4.9)
152 691 22 (1.58)
Aapro 200826 NeoRecormons 30,000 IU/wk 11.5 56.0 (27-78)# i.v. prn Solid Chemo (non-
plat)
24 63 231 27.3 (2.93)
de Castro 200745 NeoRecormons 450 IU/kg/wk 10.8 61 (19-91)# iron prn
(type NR)
Solid Chemo (plat) Median 9.9 7 255 2.75 (1.02)
Long-acting: darbepoetin A
Auerbach 201049 Aranesps 500 mg Q3W 9.3 65.5 (13) Fixed i.v. Solid þ haem Chemo (plat þ
non-plat)
11.3 68 120 57 (4.52)
Canon 200627† Aranesps 500 mg Q3W 9.76 58.7 (13.1) NR Solid þ haem Chemo (NR) Mean 12.8 (SD 3.6) 261 353 74 (2.33)
Aranesps 2.25 mg QW 9.78 59.3 (12.3) NR Solid þ haem Chemo (NR) Mean 12.3 (SD 3.9) 264 352 75 (2.31)
Chemo ¼ chemotherapy; haem ¼ haematological cancers; Hb ¼ haemoglobin; i.v. ¼ intravenous; non-plat ¼ non-platinum based; NR ¼ not reported; plat ¼
platinum based; prn ¼ as required; pts ¼ patients; QW ¼ every week; Q3W ¼ every 3 weeks; SD ¼ standard deviation; SE ¼ standard error; TIW ¼ three times per
week; wk ¼ week.
*Immediate treatment group
**Delayed treatment group
#Median (range) reported
†Contributed two ESA arms.
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Supplemental Table IV. Summary of studies included in the dose withheld analysis.
Author and year ESA brand name Starting dose
Mean
baseline
Hb, g/dL
Mean
baseline age
(SD),
years Iron Tumour Chemotherapy
Actual
treatment
duration, wks
No. pts.
with
ESA dose
withheld, n
Total no.
of pts receiving
ESA, N
% pts. with
dose withheld
(SE)
Short-acting: epoetin A
Carteni 200731 Eprexs 40,000 IU per wk 10.43 60.1 (11.0) NR Solid Chemo (plat þ
non-plat)
12 118 485 24.3 (1.95)
Henry 200636 Epoetin alfa (brand NR) 40,000 IU per wk 9.9 60.9 (12.5) Fixed oral Solid Chemo (plat þ
non-plat)
Mean 8.7 61 145 42 (4.10)
Glaspy 199740 Procrits 150 IU/kg TIW 9.3 63.7 (11.6) NR Solid þ haem Chemo (pla tþ
non-plat)
17.3 119 233 51.1 (3.28)
Steensma 200933 Epoetin alfa (Brand NR) 40, 000 IU per wk NR NR Fixed oral Solid þ haem Chemo (plat þ
non-plat)
Maximum 15 NR NR (assumed 59
(236/4)
63.9
Short-acting: epoetin B
de Castro 200745 NeoRecormons 450 IU/kg per wk 10.8 61 (19-91)# iron prn
(type NR)
Solid Chemo (plat) Median 9.9 32 255 12.55 (2.08)
Long-acting: darbepoetin A
Auerbach 201049 Aranesps 500 mg Q3W 9.3 65.5 (13) Fixed i.v. Solid þ haem Chemo (plat þ
non-plat)
11.3 68 120 20 (3.65)
Kotasek 200748 Aranesps 2.25mg QW 9.6 61.9 NR Solid þ haem Chemo (NR) 16 127 380 33 (2.41)
Steensma 200933 Aranesps 500 mg every 3wks NR NR Fixed oral Solid þ haem Chemo (plat þ
non-plat)
Maximum 15 NR NR (assumed 59
(236/4)
43.6
Chemo ¼ chemotherapy; haem ¼ haematological cancers; Hb ¼ haemoglobin; i.v. ¼ intravenous; non-plat ¼ non-platinum based; NR ¼ not reported; plat ¼
platinum based; prn ¼ as required; pts ¼ patients; QW ¼ every week; Q3W ¼ every 3 weeks; SD ¼ standard deviation; SE ¼ standard error; TIW ¼ three times per
week; wk ¼ week.
#Median (range) reported
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